Synairgen noted that Pharmaxis has reported receipt of all data for the LOXL2 inhibitor candidates in three-month toxicity studies. These data complete the overall package required for Pharmaxis' partnering discussions. In November 2018 Pharmaxis announced the successful completion of the Phase I single and multiple ascending dose trials of their two LOXL2 inhibitor compounds. Data from the Phase I trials support once daily oral dosing and demonstrated best-in-class inhibition of the LOXL2 enzyme. Together with preclinical data in models of fibrosis, this package shows the potential of these compounds to target diseases associated with LOXL2 such as Non-alcoholic Steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).